Perspective
Jun. 18, 2013
How Myriad's once unthinkable result became expected
Amazingly, shares of Myriad and other biotech companies rose in the immediate reaction to the decision. By Joe Liebeschuetz
Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., No. 12-398, finally concluded last week with the Supreme Court holding that isolated genes lie outside the contours of patent-eligible subject matter. The decision implies invalidity of analogous claims in thousands of other patents. Amazingly, shares of Myriad and other biotech companies rose in the immediate reaction to the decision.
The stock m...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In